Stocktoria
Prelude Therapeutics Inc PRLD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-25
Chart by TradingView
3/9
Piotroski F — financial health
-17.29
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $12.1M | $7.0M | — | — | — |
| Operating income | -$104.6M | -$139.7M | -$132.3M | -$123.5M | -$113.7M |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M | -$111.7M |
| Operating cash flow | -$56.3M | -$102.9M | -$107.1M | -$83.7M | -$83.5M |
| Free cash flow | -$56.4M | -$103.7M | -$110.6M | -$86.7M | -$85.9M |
| Total assets | $141.3M | $175.5M | $277.7M | $220.5M | $305.1M |
| Total liabilities | $72.7M | $44.1M | $40.6M | $25.1M | $19.2M |
| Shareholders' equity | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M |
| Ratios | |||||
| Operating margin | -861.3% | -1995.9% | — | — | — |
| Net margin | -819.6% | -1816.8% | — | — | — |
| FCF margin | -464.3% | -1480.7% | — | — | — |
| Return on assets | -70.4% | -72.5% | -43.9% | -52.4% | -36.6% |
| Return on equity | -145.0% | -96.7% | -51.4% | -59.1% | -39.1% |
| Current ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 |
| Revenue growth | 73.4% | — | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 275,200 | $941,184 |
| Point72 Asset Management, L.P. | 16,329 | $55,845 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -17.29 (distress)
- Working capital / assets 0.373
- Retained earnings / assets -4.834
- EBIT / assets -0.74
- Equity / liabilities 0.944
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001678660 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.